Literature DB >> 18976013

Histopathologic and clinical features of medullary microcarcinoma and C-cell hyperplasia in prophylactic thyroidectomies for medullary carcinoma: a study of 42 cases.

Demet Etit1, William C Faquin, Randall Gaz, Gregory Randolph, Ronald A DeLellis, Ben Z Pilch.   

Abstract

CONTEXT: Prophylactic thyroidectomies are increasingly performed on patients at risk for developing medullary thyroid carcinoma (MTC); consequently, pathologists are more commonly encountering these specimens in routine practice.
OBJECTIVE: To describe the detailed clinicopathologic features of prophylactic thyroidectomies for medullary carcinoma.
DESIGN: We present a retrospective series of 42 prophylactic thyroidectomies for MTC performed for one or more of the following: family history of multiple endocrine neoplasia (MEN) or MTC, elevated serum calcitonin level, or detection of a RET proto-oncogene mutation.
RESULTS: Patients included 22 men and 20 women (mean age, 26.2 years). Among those with known RET proto-oncogene mutations, affected sites included exons 10, 11, 14, and 16. In 93% (n = 39) of cases, either C-cell hyperplasia (n = 36), medullary microcarcinoma (MMC; n = 29), or medullary macrocarcinoma (n = 1) was found. C-cell hyperplasia was often multifocal (n = 30) and bilateral (n = 23) and included both nonnodular and nodular patterns. A total of 94% of C-cell hyperplasia cases and all MMC cases were microscopically detectable using hematoxylin-eosin stains. The MMCs were characterized by a complex microarchitectural pattern with a desmoplastic stromal response (n = 29) and focal amyloid deposition (n = 12). Most MMCs exhibited a solid pattern (n = 24) of round, polygonal, spindled, or plasmacytoid-shaped cells. Only 1 case of MMC showed evidence of metastatic disease to a pretracheal lymph node.
CONCLUSIONS: Based upon our clinicopathologic findings and review of the literature, we conclude that thyroidectomies in at-risk patients are very frequently associated with C-cell hyperplasia and/or MMC; however, the clinical prognosis for these patients is very good.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18976013     DOI: 10.5858/132.11.1767

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  5 in total

1.  Prevalence by age and predictors of medullary thyroid cancer in patients with lower risk germline RET proto-oncogene mutations.

Authors:  Thereasa A Rich; Lei Feng; Naifa Busaidy; Gilbert J Cote; Robert F Gagel; Mimi Hu; Camilo Jimenez; Jeffrey E Lee; Nancy Perrier; Steven I Sherman; Steven G Waguespack; Anita Ying; Elizabeth Grubbs
Journal:  Thyroid       Date:  2014-06-06       Impact factor: 6.568

Review 2.  Management of medullary thyroid carcinoma and MEN2 syndromes in childhood.

Authors:  Steven G Waguespack; Thereasa A Rich; Nancy D Perrier; Camilo Jimenez; Gilbert J Cote
Journal:  Nat Rev Endocrinol       Date:  2011-08-23       Impact factor: 43.330

Review 3.  Neuroendocrine Tumors of the Thyroid and Their Mimics.

Authors:  Virginia A Livolsi
Journal:  Endocr Pathol       Date:  2021-03-09       Impact factor: 3.943

Review 4.  Multiple Endocrine Neoplasia: A Genetically Diverse Group of Familial Tumor Syndromes.

Authors:  M Cristina Pacheco
Journal:  J Pediatr Genet       Date:  2016-03-09

5.  False positive results using calcitonin as a screening method for medullary thyroid carcinoma.

Authors:  Rafael Loch Batista; Andrea Cecilia Toscanini; Lenine Garcia Brandão; Malebranche Berardo C Cunha-Neto
Journal:  Indian J Endocrinol Metab       Date:  2013-05
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.